Business
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer Preclinical characterization of FHT-171, a selective CBP degrader with promise in ER+ breast cancer Progress across Selective EP300 degrader in hematological malignancies and Selective ARID1B degrader in ARID1A-mutant tumors WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a
About this update from Foghorn Therapeutics Inc.
[{"type":"image","alt":"Foghorn Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Foghorn Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/c48e0461026ebce223e5a31638f2e086"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lZQs0UgtmfP013MY5QJUpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNQ--/https://media.zenfs.com/en/globenewswire.com/c48e0461026ebce223e5a31638f2e086","width":300,"height":75},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/lZQs0UgtmfP013MY5QJUpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNQ--/https://media.zenfs.com/en/globenewswire.com/c48e0461026ebce223e5a31638f2e086","width":300,"height":75}},"lazy":false},{"type":"text","content":"New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer","length":177,"tagName":"p"},{"type":"text","content":"Preclinical characterization of FHT-171, a selective CBP degrader with promise in ER+ breast cancer","length":99,"tagName":"p"},{"type":"text","content":"Progress across Selective EP300 degrader in hematological malignancies and Selective ARID1B degrader in ARID1A-mutant tumors","length":125,"tagName":"p"},{"type":"text","content":"WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will have multiple oral and poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026, in San Diego, California. New preclinical data for Selective SMARCA2 inhibitor FHD-909 will be featured as part of an oral presentation and preclinical data for Selective CBP, Selective EP300, and Selective ARID1B degrader programs will be featured as poster presentations.","length":690,"tagName":"p"},{"type":"text","content":"“FHD-909 is advancing in the clinic in collaboration with Lilly as the first potential selective SMARCA2 inhibitor for the treatment of SMARCA4-mutant cancers. We are excited to present new, compelling preclinical data further supporting potential expansion opportunities in combination with an anti...